New Delhi, Feb 17 (PTI) Homegrown pharma major Lupin Ltd on Thursday said it has received approval from the US health regulator for its supplemental New Drug Application (sNDA) for usage of its antibiotic Solosec in adolescents for treatment of both bacterial vaginal infection in females and sexually transmitted infection, trichomoniasis.

The US Food and Drug Administration (USFDA) has approved the company's sNDA to expand the use of Solosec in the treatment of bacterial vaginosis (BV) for female patients 12 years of age and older and in the treatment of trichomoniasis for all patients 12 years of age and above, Lupin Ltd said in a regulatory filing.

Also Read | OnePlus TV Y1S, OnePlus TV Y1S Edge With Android TV 11 Launched; Check Prices & Other Details Here.

"The supplemental adolescent approval enhances Solosec's strong position as the first and only single-dose oral prescription antimicrobial agent approved for the treatment of both trichomoniasis and BV," it said.

Commenting on the approval, Lupin Executive Director - Specialty, Tom Merriam said, "This expansion brings to health care professionals a treatment option for both BV and trichomoniasis in adolescents which provides a complete course of therapy in a single dose..."

Also Read | OnePlus Nord CE 2 5G Launched in India at Rs 23,999; First Sale on February 22, 2022.

This will helps address gaps in care related to adherence and may reduce risk factors associated with BV and trichomoniasis, such as other sexually transmitted diseases, Merriam added.

Solosec is an oral antibiotic used to treat bacterial vaginosis in adult women and also in treating Trichomoniasis, a common sexually transmitted infection (STI), in adults.

(The above story is verified and authored by Press Trust of India (PTI) staff. PTI, India’s premier news agency, employs more than 400 journalists and 500 stringers to cover almost every district and small town in India.. The views appearing in the above post do not reflect the opinions of LatestLY)